Drug intelligence / Profile preview

IPN01195

Development stage: Phase 2
Lead developer: Ipsen
Modality: Small Molecules
Administration: Oral

Overview

IPN01195 is an investigational RAF inhibitor developed by Ipsen for the treatment of advanced solid tumors. It is currently being evaluated in a phase 1/2 clinical trial to determine its appropriate dosage, safety, and effectiveness as a single agent in adults with advanced malignant solid neoplasms. The drug targets the MAPK pathway through inhibition of RAF kinases, which play a key role in cell proliferation and survival signaling pathways often dysregulated in cancer[1][2][3][5]. Clinical development is ongoing primarily in the United States.

Targets

RAF1 (c-Raf-1 (Y340D/Y341D))

Beyond the preview

Go deeper on IPN01195.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IPN01195.

Explore the full profile